Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Receptor-mediated Endocytosis01:38

Receptor-mediated Endocytosis

Overview
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Divergent activation of the RXFP1 relaxin receptor by protein and small molecule agonists.

bioRxiv : the preprint server for biology·2026
Same author

Targeting lysosomal pH restores mitochondrial quality control in GBA1-mutant Parkinson's disease.

Translational neurodegeneration·2026
Same author

Coil-Tag Conjugation: A Next Gen Site-Specific ADC Fabrication Technology.

Bioconjugate insights·2026
Same author

Peptide Tag-nology for Preparation of Site-Specific Antibody-Drug Conjugates.

Bioconjugate chemistry·2026
Same author

Biosynthesis of 6-thioguanine: characterizing two intermediates involved in its thioamide formation reaction.

ACS catalysis·2026
Same author

Bioengineered systems to exploit tumor microenvironment metabolism.

Trends in cancer·2026

Related Experiment Video

Updated: Jun 4, 2026

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
08:29

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

Reduction-triggered delivery using nucleoside-lipid based carriers possessing a cleavable PEG coating.

Khalid Oumzil1, Salim Khiati, Mark W Grinstaff

  • 1INSERM U869, Bordeaux, France.

Journal of Controlled Release : Official Journal of the Controlled Release Society
|March 1, 2011
PubMed
Summary

A novel nucleoside-based lipid, DOU-SS-PEG(2000), enables targeted drug delivery. This lipid facilitates reduction-triggered release and enhanced cellular uptake in ovarian cancer cells, improving therapeutic potential.

More Related Videos

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Related Experiment Videos

Last Updated: Jun 4, 2026

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA
08:29

Generation of Cationic Nanoliposomes for the Efficient Delivery of In Vitro Transcribed Messenger RNA

Published on: February 1, 2019

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform
09:41

Formulating and Characterizing Lipid Nanoparticles for Gene Delivery using a Microfluidic Mixing Platform

Published on: February 25, 2021

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes
10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

Area of Science:

  • Biomaterials Science
  • Drug Delivery Systems
  • Nanotechnology

Background:

  • Nucleoside-based lipids offer unique properties for drug delivery.
  • Poly(ethylene glycol) (PEG)ylation is crucial for nanoparticle stability and circulation.
  • Thiolytic cleavable linkers allow for triggered release of therapeutic agents.

Purpose of the Study:

  • To synthesize and characterize a novel non-ionic nucleoside-based lipid, DOU-SS-PEG(2000), for drug delivery.
  • To evaluate the reduction-triggered release and cellular internalization of liposomal and micellar systems formulated with DOU-SS-PEG(2000).
  • To investigate the morphology transition of supramolecular systems upon disulfide bond cleavage.

Main Methods:

  • Convergent synthesis of DOU-SS-PEG(2000) from HS-PEG-OMe and uridine.
  • Preparation of liposomes and micelles using DOU-SS-PEG(2000) and DOPE-rhodamine.
  • Characterization of supramolecular systems using Dynamic Light Scattering (DLS), zeta potential, and Transmission Electron Microscopy (TEM).
  • Evaluation of cellular internalization in SKOV3 ovarian cancer cells using fluorescence microscopy after dithiothreitol (DTT) treatment.

Main Results:

  • DOU-SS-PEG(2000) was successfully synthesized and incorporated into liposomal and micellar formulations.
  • Reduction-triggered cleavage of the disulfide bond in PEG chains exposed a cationic surface, enhancing liposome internalization.
  • Significant increase in cellular uptake was observed in SKOV3 cells treated with DTT-activated liposomes and micelles.
  • Morphological transition from micellar to vesicular states was induced by reduction.

Conclusions:

  • DOU-SS-PEG(2000) is a promising building block for stimuli-responsive drug delivery systems.
  • The reduction-triggered release mechanism enhances cellular delivery efficiency, particularly in cancer cells.
  • This nucleoside-based lipid offers a versatile platform for developing advanced nanomedicines.